Osteolysis: Clinical Trials

2 trials for Osteolysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow Osteolysis: new trials by email Literature Review of Osteolysis trials Research Report on Osteolysis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration - Refractory Multiple Myeloma
Phase 2CompletedNational Cancer Institute (NCI)162011-11-012019-08-28
Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements
Placebo, Apatone®B - Edematous, Synovitis
Phase 2CompletedIC-MedTech Corporation572010-10-012018-01-31

Narrower conditions

Amyloidosis (1)  ·  Anemia (1)  ·  Bone Diseases, Metabolic (1)  ·  Edema (1)  ·  Foreign-Body Reaction (1)  ·  Fractures, Spontaneous (1)  ·  Hematologic Neoplasms (1)  ·  Hypercalcemia (1)  ·  Multiple Myeloma (1)  ·  Paraproteinemias (1)  ·  Renal Insufficiency (1)  ·  Synovitis (1)

Broader conditions

Bone Diseases (2)  ·  Bone Resorption (2)  ·  Musculoskeletal Diseases (2)  ·  Wounds and Injuries (2)  ·  Blood Protein Disorders (1)  ·  Calcium Metabolism Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Foreign Bodies (1)  ·  Fractures, Bone (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)

Interventions

ARQ 197 (1)

Sponsors

IC-MedTech Corporation (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (2)

Top investigators

Mark W Kovacik, BS (1)  ·  Robert Orlowski (1)  ·  Thomas F Bear, MD (1)

NIH funding

N01CM00039 (1), P30CA016672 (1), U01CA062461 (1)